Desmond Y. H. Yap, Kevin S. H. Liu, Yu-Chun Hsu, Grace L. H. Wong, Ming-Chang Tsai, Chien-Hung Chen, Ching-Sheng Hsu, Yee Tak Hui, Michael K. K. Li, Chen-Hua Liu, Yee-Man Kan, Ming-Lung Yu, Man-Fung Yuen
Clin Mol Hepatol 2020;26(4):554-561. Published online August 28, 2020
Background/Aims Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with non-1 genotype (GT) HCV.
Methods We prospectively recruited patients with Child’s A cirrhosis and eGFR <30 mL/min/1.73 m2 in Hong Kong and Taiwan during 2017–2018 to receive GLE/PIB treatment.
Result s: Twenty-one patients (GT2, n=7; GT3, n=6; and GT6, n=8) received GLE/PIB for 11.2±1.8 weeks. All except one were treatment-naïve. GLE/PIB was initiated in 16 patients while on dialysis (seven on peritoneal dialysis [PD] and nine on hemodialysis) and in five patients before dialysis. One patient died of PD-related peritonitis during treatment and two were lost to follow up. The SVR12 rate in the remaining 18 patients was 100%. All patients achieved undetectable levels at 4-, 12-, 24- and 48-week after treatment. Patients with deranged alanine aminotransferase showed normalization after 4 weeks and the response was sustained for 48 weeks. No significant adverse event was observed.
Conclusions GLE/PIB treatment was associated with high efficacy and tolerability in HCV-infected patients with severe renal impairment.
Citations
Citations to this article as recorded by
Glecaprevir/Pibrentasvir Versus Sofosbuvir/Velpatasvir for Hepatitis C Virus Genotype 6: A Systematic Review and Meta‐Analysis Duong Hoang Huy Le, Dinh Chuong Nguyen, Sitthichai Kanokudom, Jiratchaya Puenpa, Pornjarim Nilyanimit, Anh Ngoc Tran, Sittisak Honsawek, Yong Poovorawan Reviews in Medical Virology.2025;[Epub] CrossRef
Direct-Acting Antivirals in Hepatitis C Treatment for Renal Impairment: Liver Safety Concerns and Effectiveness in Peritoneal Dialysis Hsuan-Yu Hung, Wei-Liang Hung, Ye Gu, Chung-Yu Chen Biomedicines.2024; 13(1): 55. CrossRef
The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis Ruochan Chen, Yinghui Xiong, Yanyang Zeng, Xiaolei Wang, Yinzong Xiao, Yixiang Zheng Frontiers in Public Health.2023;[Epub] CrossRef
Glecaprevir/Pibrentasvir and Renal Dysfunction in Deceased Donor Renal Transplantation: A Case Report Akari Kaba, Shigeyoshi Yamanaga, Yuji Hidaka, Mariko Toyoda, Masayuki Kashima, Yoshi Takekuma, Akito Inadome, Hiroshi Yokomizo, Akira Miyata Transplantation Proceedings.2022; 54(2): 549. CrossRef
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C Jyh-Jou Chen, Yen-Cheng Chiu, Pei-Lun Lee, Hung-Da Tung, Hung-Chih Chiu, Shih-Chieh Chien, Pin-Nan Cheng Journal of the Formosan Medical Association.2022; 121(11): 2265. CrossRef
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5 Chen-Hua Liu, Jia-Horng Kao Hepatology International.2022; 16(5): 1001. CrossRef
Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease Ji Eun Ryu, Myeong Jun Song, Seok-Hwan Kim, Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Chul Nam, Hee Yeon Kim, Chang Wook Kim, Hyun Yang, Si Hyun Bae, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Soon Kyu Lee, Pil Soo Sung, Jeong The Korean Journal of Internal Medicine.2022; 37(5): 958. CrossRef
Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease Fabrizio Fabrizi, Federica Tripodi, Roberta Cerutti, Luca Nardelli, Carlo M. Alfieri, Maria F. Donato, Giuseppe Castellano Viruses.2022; 14(11): 2570. CrossRef
Drug-drug interactions with direct-acting antivirals — less is more Grace Lai-Hung Wong Clinical and Molecular Hepatology.2021; 27(1): 81. CrossRef
More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis Paul Kwo, Deepti Dronamraju Clinical and Molecular Hepatology.2020; 26(4): 489. CrossRef
First
Prev
